Q32 Bio Inc.
QTTB
$1.95
$0.063.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -27.46% | 68.79% | 26.45% | 92.23% | -95.19% |
| Gross Profit | 27.46% | -68.79% | 54.15% | -156.00% | 91.98% |
| SG&A Expenses | -11.05% | 2.04% | 41.77% | 103.65% | 83.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.82% | -23.84% | 30.31% | 94.82% | 70.98% |
| Operating Income | 48.82% | 23.84% | 43.72% | -141.27% | -146.31% |
| Income Before Tax | 44.11% | -1,172.01% | 41.10% | -25.98% | -192.37% |
| Income Tax Expenses | -- | -- | -733.99% | -- | -- |
| Earnings from Continuing Operations | 44.11% | -1,172.01% | 47.58% | -25.40% | -192.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.11% | -1,172.01% | 47.58% | -25.40% | -192.37% |
| EBIT | 48.82% | 23.84% | 43.72% | -141.27% | -146.31% |
| EBITDA | 48.98% | 24.01% | 43.91% | -143.56% | -148.89% |
| EPS Basic | 45.18% | -187.47% | 98.47% | 96.40% | 91.50% |
| Normalized Basic EPS | 45.18% | -179.36% | 95.53% | 96.53% | 91.50% |
| EPS Diluted | 45.07% | 85.71% | 98.47% | 96.40% | 91.49% |
| Normalized Diluted EPS | 45.18% | -286.13% | 95.53% | 96.53% | 91.50% |
| Average Basic Shares Outstanding | 1.95% | 1,125.52% | 3,336.99% | 3,387.27% | 3,338.98% |
| Average Diluted Shares Outstanding | 1.95% | 422.56% | 3,336.99% | 3,387.27% | 3,338.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |